Figure 5

Probabilistic results of the incremental cost-effectiveness differences between treatment with combination therapy (ADV+LMV) and with (A) no treatment, (B) ADV monotherapy, (C) ETV monotherapy and (D) TDF monotherapy for a cohort of 1,000 LAM-resistant HBeAg-positive and HBeAg-negative chronic hepatitis B patients. The y-axis represents the incremental costs. The x-axis represents the incremental quality-adjusted life years (QALYs) gained. Dots that lie below the ICER threshold (the oblique lines) reflect simulations in which the cost per additional QALY gained with combination therapy was below the ICER threshold.